Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  BGI Genomics Co., Ltd.    300676   CNE100003449

BGI GENOMICS CO., LTD.

(300676)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at CNY 106.02, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the CNY 118.38 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • With a P/E ratio at 14.51 for the current year and 32 for next year, earnings multiples are highly attractive compared with competitors.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The stock is in a well-established, long-term rising trend above the technical support level at 106.02 CNY
Weaknesses
  • The company's earnings releases usually do not meet expectations.
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
BGI GENOMICS CO., LTD.85.74%7 687
-
EXACT SCIENCES CORPORATION25.29%18 427
GUARDANT HEALTH, INC.44.15%11 261
INVITAE CORPORATION190.45%8 278
ADAPTIVE BIOTECHNOLOGIES CO..53.18%6 268
IOVANCE BIOTHERAPEUTICS, IN..37.07%5 565
-
SEEGENE INC--.--%4 255
VERACYTE, INC.82.31%2 947
CAREDX, INC159.99%2 762
Q-LINEA AB (PUBL)190.43%529
BIOVICA INTERNATIONAL AB (P..244.07%135
EPIGENOMICS AG-66.81%25
More Results
Financials
Sales 2020 8 985 M 1 366 M 1 366 M
Net income 2020 3 530 M 537 M 537 M
Net Debt 2020 - - -
P/E ratio 2020 14,5x
Yield 2020 0,15%
Capitalization 50 701 M 7 711 M 7 709 M
Capi. / Sales 2020 5,64x
Capi. / Sales 2021 9,46x
Nbr of Employees -
Free-Float 100,0%
Upcoming event on BGI GENOMICS CO., LTD.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability -
P/E ratio
Potential -
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision -
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes